[:en]
We draw the attention of research teams and future partners wishing to apply on this line that the obtaining or the existence of an orphan drug designation is an eligibility criterion.
In addition, taking into account the recommendations of the European Medicines Agency (EMA) via protocol assistance in the design of the clinical trial and a clear patient recruitment strategy are also prerequisites of the call for projects.
[:]